Soleus Capital Management L.P. Trims Position in Bausch + Lomb Co. (NYSE:BLCO)

Soleus Capital Management L.P. trimmed its position in shares of Bausch + Lomb Co. (NYSE:BLCO) by 61.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 120,500 shares of the company’s stock after selling 191,500 shares during the period. Soleus Capital Management L.P.’s holdings in Bausch + Lomb were worth $2,176,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Blue Trust Inc. grew its holdings in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after buying an additional 1,004 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in shares of Bausch + Lomb during the fourth quarter worth $181,000. Alpine Global Management LLC bought a new position in shares of Bausch + Lomb during the fourth quarter worth $181,000. Covestor Ltd purchased a new position in Bausch + Lomb during the fourth quarter valued at $188,000. Finally, Orion Portfolio Solutions LLC bought a new stake in Bausch + Lomb in the 4th quarter valued at $225,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Price Performance

Shares of Bausch + Lomb stock opened at $11.77 on Monday. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -12.93, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60. The stock has a 50 day moving average price of $13.03 and a 200-day moving average price of $16.24. Bausch + Lomb Co. has a one year low of $10.45 and a one year high of $21.69.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the previous year, the firm earned $0.07 earnings per share. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. Equities analysts expect that Bausch + Lomb Co. will post 0.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wells Fargo & Company cut their price objective on Bausch + Lomb from $15.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, May 1st. Evercore ISI dropped their price target on Bausch + Lomb from $19.00 to $15.50 and set an “outperform” rating for the company in a research note on Thursday, May 1st. Royal Bank of Canada cut their price target on Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, April 4th. Bank of America decreased their price objective on Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating on the stock in a report on Thursday, February 20th. Finally, Morgan Stanley cut their target price on shares of Bausch + Lomb from $18.00 to $12.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and a consensus price target of $15.50.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.